Tci Wealth Advisors, Inc. Nurix Therapeutics, Inc. Transaction History

Tci Wealth Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$8.56 - $13.26 $3,038 - $4,707	355 New	355 $3,000
Q2 2022 Jul 19, 2022	SELL	$7.88 - $14.82 $2,119 - $3,986	-269 Closed	0 $0
Q1 2022 Apr 29, 2022	BUY	$12.94 - $29.65 $2,575 - $5,900	199 Added 284.29%	269 $4,000
Q4 2021 Jan 24, 2022	BUY	$26.43 - $34.5 $79 - $103	3 Added 4.48%	70 $2,000
Q2 2021 Aug 02, 2021	BUY	$24.21 - $35.89 $1,622 - $2,404	67 New	67 $2,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.03B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.